- Home
- THTX vs VOR Comparison
THTX vs VOR Comparison
Compare THTX & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THTX
- VOR
- Stock Information
- Founded
- THTX 1993
- VOR 2015
- Country
- THTX Canada
- VOR United States
- Employees
- THTX N/A
- VOR N/A
- Industry
- THTX Biotechnology: Pharmaceutical Preparations
- VOR Biotechnology: Pharmaceutical Preparations
- Sector
- THTX Health Care
- VOR Health Care
- Exchange
- THTX Nasdaq
- VOR Nasdaq
- Market Cap
- THTX 119.1M
- VOR 202.4M
- IPO Year
- THTX N/A
- VOR 2021
- Fundamental
- Price
- THTX $3.15
- VOR $2.30
- Analyst Decision
- THTX Hold
- VOR Buy
- Analyst Count
- THTX 1
- VOR 7
- Target Price
- THTX N/A
- VOR $3.77
- AVG Volume (30 Days)
- THTX 1.0M
- VOR 47.3M
- Earning Date
- THTX 07-09-2025
- VOR 08-07-2025
- Dividend Yield
- THTX N/A
- VOR N/A
- EPS Growth
- THTX N/A
- VOR N/A
- EPS
- THTX N/A
- VOR N/A
- Revenue
- THTX $84,378,000.00
- VOR N/A
- Revenue This Year
- THTX N/A
- VOR N/A
- Revenue Next Year
- THTX $15.13
- VOR N/A
- P/E Ratio
- THTX N/A
- VOR N/A
- Revenue Growth
- THTX 2.19
- VOR N/A
- 52 Week Low
- THTX $1.12
- VOR $0.13
- 52 Week High
- THTX $3.20
- VOR $3.29
- Technical
- Relative Strength Index (RSI)
- THTX 73.35
- VOR 78.77
- Support Level
- THTX $2.28
- VOR $2.25
- Resistance Level
- THTX $3.20
- VOR $3.29
- Average True Range (ATR)
- THTX 0.07
- VOR 0.52
- MACD
- THTX 0.07
- VOR 0.18
- Stochastic Oscillator
- THTX 94.79
- VOR 82.52
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.